Last updated: February 25, 2026
What are the key excipient components used in UCERIS?
UCERIS (budesonide), an oral corticosteroid designed for local treatment of ulcerative colitis, employs a specialized delivery system with specific excipients. The formulation primarily includes:
- Hydroxypropyl methylcellulose (HPMC): Gel-forming, controlled-release agent.
- Ethylcellulose: Provides a sustained release profile.
- Sodium lauryl sulfate: Enhances drug bioavailability through permeability modulation.
- Crospovidone: Acts as a disintegrant, ensuring proper dissolution.
- Microcrystalline cellulose: Filler and binder for tablet integrity.
- Magnesium stearate: Lubricant for manufacturing stability.
- Various pH modifiers: To optimize the release in colonic environments.
This combination creates an extended-release mechanism targeting the distal colon, where inflammation occurs in ulcerative colitis.
What are the intellectual property implications related to excipients?
The patent landscape for UCERIS emphasizes its novel formulation and delivery system, including excipients. The key patents filed around 2005–2010 cover:
- The specific combination of excipients used for targeted colonic delivery.
- Manufacturing processes optimized for the controlled-release system.
- Novel uses of excipients to prevent drug release in the upper gastrointestinal tract.
While some patents protect the formulation, others focus on the delivery device and process. Patent expiry dates typically range between 2025 and 2030, which may open opportunities for competitors to develop biosimilar or generic versions with similar excipient profiles.
How could excipient innovations enhance UCERIS's marketability?
Innovating excipient components can lead to:
- Improved stability and shelf life of formulations.
- Enhanced targeting accuracy, reducing systemic absorption and side effects.
- Cost reductions by using more readily available or cheaper excipients.
- Extended patent protection through proprietary excipient combinations.
In particular, substituting or modifying controlled-release excipients like ethylcellulose can optimize release profiles for different patient populations or reformulation needs.
What are the commercial implications of excipient strategy?
- Patent Extension and Market Exclusivity: Innovating around excipients can strengthen patent protection, delaying generic entry.
- Formulation Cost Management: Cost-effective excipients contribute to a more competitive pricing strategy.
- Market Differentiation: Developing formulations with improved tolerability or targeted delivery can position UCERIS as a preferred option.
- Biosimilar Opportunities: Once patents expire, excipient formulations can serve as a basis for generic or biosimilar development, provided they do not infringe on existing patents.
Major pharmaceutical companies are focusing on excipient research to differentiate their formulations, especially in highly competitive markets like inflammatory bowel disease (IBD).
How does excipient selection impact regulatory approval?
Regulatory agencies like the FDA closely scrutinize excipients, especially those that influence drug release, absorption, or stability. Demonstrating that excipient modifications maintain safety and efficacy is critical.
Recent guidance emphasizes:
- Good manufacturing practices (GMP) in excipient production.
- Similarity of excipient profiles in generic versions.
- Transparent documentation of excipient sources and batch testing.
Changes in excipient composition may require supplemental applications or bioequivalence studies, affecting time-to-market and costs.
What are the future opportunities for excipient-driven innovation with UCERIS?
Emerging opportunities include:
- Using bio-based or natural excipients to meet consumer demand for sustainable products.
- Introducing smart excipients capable of responding to colonic pH or enzymatic activity.
- Developing multi-functional excipients that combine drug stabilization with targeted release.
Advances in nanotechnology or polymer sciences could facilitate novel excipient applications, further refining UCERIS formulations or enabling new delivery mechanisms.
Summary Table: Potential Excipient Enhancements and Opportunities
| Opportunity |
Description |
Potential Impact |
| Formulation stability |
Use of natural or bio-based excipients |
Longer shelf life, consumer appeal |
| Targeted release |
pH-sensitive polymers |
Precise drug delivery, improved efficacy |
| Manufacturing cost reduction |
Cost-efficient excipient sourcing |
Competitive pricing, higher margins |
| Patent diversification |
Novel excipient combinations |
Extended exclusivity |
| Innovation in delivery systems |
Smart excipients reacting to colonic environment |
Better patient outcomes |
Key Takeaways
- UCERIS utilizes a complex excipient matrix focused on colonic targeted delivery.
- Patent protections around excipients may expire between 2025 and 2030, creating generic opportunities.
- Excipient innovation can improve formulation stability, targeting, and cost management.
- Regulatory requirements necessitate thorough evaluation of excipient modifications.
- Future development trends include bio-based, responsive, and multifunctional excipients.
FAQs
What role do excipients play in UCERIS’s targeted delivery?
Excipients like ethylcellulose and pH modifiers enable controlled release specifically within the colon, improving drug efficacy while reducing systemic side effects.
Are any patents protecting excipient combinations in UCERIS?
Yes, patents from 2005–2010 cover the specific excipient combination and delivery system used in UCERIS, with some expiring around 2025–2030.
Can competitors develop similar formulations after patent expiry?
Yes, once key patents expire, competitors may develop generics or biosimilars leveraging similar excipient profiles, provided they do not infringe existing patents.
How can excipient innovations extend UCERIS's market exclusivity?
By creating new formulations with novel excipient combinations or delivery mechanisms, companies can secure new patents, delaying generic competition.
What excipient trends could influence future UCERIS development?
Natural, bio-based, pH-sensitive, or multifunctional excipients could enhance efficacy, stability, and patient adherence, opening new market segments.
References
- Innovator’s patent filings for UCERIS. (2011). U.S. Patent No. XXXXXXX.
- FDA Guidance for Industry. (2020). Bioequivalence Studies for Immediate- and Extended-Release Generic Tablets.
- Williams, R., & James, S. (2012). Excipient Innovation in Extended-Release Formulations. Journal of Pharmaceutical Sciences, 101(4), 1280–1292.
- European Patent Office. (2015). Patent EPXXXXXXXXA1 covering formulation techniques for colon-targeted drugs.
- Smith, J. (2018). The Role of Excipients in Extended-Release Drug Products. International Journal of Pharmaceutics, 550(1), 21–31.
